> > Immunocan

Immunocan

Immunocan raises RMB 250M Series A

Immunocan Shanghai Immunocan Biotech Co., Ltd., a Shanghai-based antibody discovery platform, raised RMB 250 million in a Series A fundraising round led by Vivo Capital with participation from Gold Mine Multi Family Office.

Similar Health deals

Violet Therapeutics, a Norwalk, CT-based preclinical neurodegeneration...

Regulate, a Munich-based science-backed breathwork platform, raised €1.4...

NanoStruct, a Würzburg, Germany-based same-day pathogen detection...

CVRD Health, a Miami-based healthcare services platform, raised $5 million...

Nourish, a New York-based metabolic health clinic, raised $100 million in...

Vêtir, a New York-based AI platform for luxury fashion, raised $5.5...

Stay informed on industry shifts, deal trends, and career opportunities in venture capital.

Get the latest VC moves in your inbox

Search for more jobs